Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1628 • ACR Convergence 2022
The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome
Raphaèle Seror¹, Gabriel Baron², Divi CORNEC³, Elodie Perrodeau², Marine Camus⁴, Professor Simon Bowman⁵, Michele Bombardieri⁶, Hendrika Bootsma⁷, Suzanne Arends⁷, jacques-eric gottenberg⁸, Benjamin A. Fisher⁹, Wolfgang Hueber¹⁰, Joel Van Roon¹¹, Valerie Devauchelle¹², Liseth de Wolff¹³, Peter Gergely¹⁴, Xavier Mariette¹⁵ and Raphaël Porcher¹⁶, ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³CHRU Brest, Brest, France, ⁴Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, ⁵University Hospitals Birmingham, Birmingham, United Kingdom, ⁶Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸Strasbourg University Hospital, Strasbourg, France, ⁹University of Birmingham, Birmingham, United Kingdom, ¹⁰Novartis Pharmaceuticals, Basel, Switzerland, ¹¹Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, ¹²Université de Bretagne Occidentale, Brest, France, ¹³UMCG, Zwolle, Netherlands, ¹⁴Novartis Pharma, Basel, Switzerland, ¹⁵Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁶Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
Abstract Number: 2028 • ACR Convergence 2022
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
Martha S. van Ginkel¹, Andor WJM Glaudemans¹, Bert van der Vegt¹, Arjan Vissink¹, Frans Kroese² and Hendrika Bootsma², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
Abstract Number: 2044 • ACR Convergence 2022
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
Elodie Riviere¹, Juliette Pascaud¹, Franck Letourneur², Gaetane Nocturne³ and Xavier Mariette⁴, ¹Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ²Genomic, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ³APHP, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France
Background/Purpose: Salivary gland epithelial cells (SGECs) are not only the target of autoimmunity in primary Sjögren's syndrome (pSS). SGECs may interact with lymphocytes and therefore…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…
Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Uzma Nakshbandi¹, Liseth de Wolff², Frans Kroese¹, Silvia Liefers³, Neelanjana Ray⁴, Gwenny Verstappen¹, Fred Spijkervet³, Marleen Nys⁵, Arjan Vissink⁶, Robert Wong⁷, Bert van der vegt³ and Hendrika Bootsma¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Bristol-Myers Squibb Company, Lawrenceville, GA, ⁵Bristol Myers Squibb, Braine-l'Alleud, Belgium, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands, ⁷Bristol Myers Squibb, Basking Ridge, NJ
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…
Abstract Number: 0307 • ACR Convergence 2021
Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?
Fu Chuen Kon¹, Mohammed Akil², Rachael Kilding², Kar-Ping Kuet², Priya Shanmugarajah³, Nigel Hoggard⁴ and Marios Hadjivassiliou³, ¹Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, ²Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom, ³Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust and University of Sheffield, Royal Hallamshire Hospital, Sheffield United Kingdom, Sheffield, United Kingdom, ⁴Academic Unit of Radiology, Royal Hallamshire Hospital, Sheffield, United Kingdom
Background/Purpose: Cerebellar ataxia is an uncommon neurological complication of Primary Sjogren’s Syndrome (PSS), with case reports being the highest level of evidence available. The underlying…
Abstract Number: 0323 • ACR Convergence 2021
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Katie Liao¹, Thilinie De Silva¹, Julie Bonin², Rachel Koelmeyer² and Alberta Hoi³, ¹Department of Rheumatology, Monash Health, Melbourne, Australia, ²Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…
Abstract Number: 0308 • ACR Convergence 2021
Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome
Yaxin Han¹, Li Long², Xixi Chen², Qing Peng², GUO TANG³, Jiajun Liu² and Yan Liu², ¹The People's Hospital of Wenjiang,China; Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China；Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), ²Department of Rheumatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), ³Chongqing Bishan People's Hospital, Chongqing, China (People's Republic)
Background/Purpose: This study aimed to evaluate the sleep quality and its influenced factors in patients with primary Sjögren's syndrome (pSS), and another purpose is to…
Abstract Number: 0530 • ACR Convergence 2021
Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
Charalampos Skarlis¹, Adrianos Nezos², Nikolaos Marketos¹, Asimina Papanikolaou³, Athanasios Tzioufas⁴, Michael Koutsilieris¹, Haralampos Moutsopoulos⁵ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²National & Kapodistrian University of Athens, Athens, Greece, ³Department of Haemopathology, "Evangelismos" Hospital, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Sjӧgren’s syndrome (SS) is an autoimmune exocrinopathy characterized by chronic salivary and lacrimal gland dysfunction. Alterations of Insulin-like growth factor (IGF) pathway has been…
Abstract Number: 0002 • ACR Convergence 2021
Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
Sarah Pringle¹, Bas Berkhof¹, Martha S. van Ginkel², Silvia Liefers¹, Bert van der vegt², Fred Spijkervet², Hendrika Bootsma¹, Arjan Vissink¹ and Frans Kroese¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with Sjögren’s syndrome (SS) suffer from significantly reduced saliva production. Saliva is important for oral health. A careful of sodium, chloride, potassium and…
Abstract Number: 0309 • ACR Convergence 2021
Lymphopenia and Leukopenia in Sjogren Syndrome
Loukas Chatzis¹, Ioanna Stergiou², Vasilis Pezoulas³, Paraskevi Voulgari⁴, Dimitrios Fotiadis⁵, Fotini Skopouli⁶, Haralampos Moutsopoulos⁷, Michael Voulgarelis¹, Athanasios Tzioufas¹ and Andreas Goules², ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, ³Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece, Ioannina, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁵Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, FORTH, Ioannina, Greece, Ioannina, Greece, ⁶Department of Nutrition and Clinical Dietetics, Harokopio University of Athens, Athens, Greece, ⁷Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Peripheral lymphopenia and leukopenia in Sjögren’s syndrome (SS) may suggest systemic disease activity and have been proposed as lymphoma predictors. However, the clinical phenotype…
Abstract Number: 0761 • ACR Convergence 2021
Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome
Briana Ndife¹, Sheri Fenel², Sandy Lewis² and Neetu Agashivala³, ¹Novartis, East Hanover, NJ, ²RTI Health Solutions, Research Triangle Park, NC, ³Novartis Pharmaceutical Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disease associated with a wide range of symptoms and long-term complications. While clinical indices are useful in…
Abstract Number: 0005 • ACR Convergence 2021
Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
Mathijs Broeren¹, Giulia Balzaretti², Jing Wang³, Patricia Groenen¹, Barbera van Schaik⁴, Tim Chataway³, Charlotte Kaffa¹, Sander Bervoets¹, Konnie Hebeda¹, Gergana Bounova⁵, Ger Pruijn¹, Tom Gordon³, Niek De Vries⁶ and Rogier Thurlings⁷, ¹Radboud University Medical Center, Nijmegen, Netherlands, ²Amsterdam, Netherlands, ³Flinders University, Adelaide, Australia, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Enpicom BV, Den Bosch, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…
Abstract Number: 0310 • ACR Convergence 2021
Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome
Martha S. van Ginkel¹, Esther Mossel², Erlin A. Haacke², Suzanne Arends³, Silvia Liefers¹, Konstantina Delli¹, Jolien F. van Nimwegen⁴, Alja J. Stel⁵, Fred Spijkervet¹, Arjan Vissink⁶, Bert van der vegt¹, Frans Kroese³ and Hendrika Bootsma³, ¹University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Center Groningen, Groningen, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Univeristy of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands
Background/Purpose: Primary Sjögren’s syndrome is a systemic autoimmune disease characterized by dryness of the mouth and eyes. The impact of the disease on salivary glands…
Abstract Number: 0839 • ACR Convergence 2021
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Lisa Christ¹, Seraphina Kissling², Ruediger B. Mueller³, Axel Finckh⁴, Benjamin Fisher⁵, Britta Maurer¹, Burkhard Moeller⁶ and Florian Kollert¹, ¹Department of Rheumatology and Immunology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland, ²Statistics and Data Management Group, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, ³Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ⁴University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ⁵Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: The variety of treatment options in RA contrasts with a lack of personalized medicine. The presence of concomitant SjS might be associated with differerences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].